Introduction
centrifugation, dialyzed for 24 h against distilled water to remove CsCl and quantified by absorbance at 260 nm as previously described (9).
cis-Diamminedichloroplatinum(II) (cisplatin*), given to pregMitochondrial DNA was extracted from tissues using the alkaline lysis nant rats at 5 mg/kg body wt, is a transplacental carcinogen procedure of Tamur and Aotsuka (10) with some modifications. Briefly, tissues were homogenized in buffer (0.25 M sucrose, 30 mM Tris, pH 7.4, 2 mM for fetal liver, kidney, nervous system and lung, resulting in EGTA) in a Dounce homogenizer and cooled to 4°C. The homogenates were tumor incidences of 22.5, 10.5, 6.1 and 7.5% respectively centrifuged at 1000 g to pellet the nuclei. Supernatants were centrifuged at in offspring grown to adulthood (1). Nonetheless, women 12 000 g for 10 min to pellet the mitochondrial fraction, which was subdiscovered to have ovarian cancer during pregnancy are sequently diluted with 100 µl suspension buffer (10 mM EDTA, 10 mM Tris, 150 mM NaCl, pH 8.0). The suspension was incubated for 5 min on ice with currently treated with single and multiple agent chemotherapy the addition of 200 µl lysing buffer (1% SDS, 0.18 N NaOH), neutralized protocols that include cisplatin or diamminecyclobutanedicarwith 175 ml of an ice-cold mixture containing 120 ml 5 M potassium acetate, boxylatoplatinum(II) (carboplatin) (2). Since the offspring of 23 .0 ml glacial acetic acid and 57.0 ml water, incubated on ice for an these pregnancies have not shown anatomic abnormalities and additional 5 min and centrifuged at 12 000 g for 5 min at 4°C. The supernatant the mothers are typically cancer-free at the time of delivery containing the mitochondria was mixed with an equal volume of phenol/ chloroform:isoamyl alcohol, 24:1, and centrifuged again for 2 min at room (3), the treatment is considered successful. However, because temperature. DNA was precipitated from the aqueous phase with 2 vol ethanol (22°C). An incubation with RNase was performed on the final precipitate, diluted in TrisϪEDTA buffer (1 mM EDTA, 10 mM Tris, pH 7.4) and the *Abbreviations: cisplatin, cis-diamminedichloroplatinum (II); DELFIA, dissociation-enhanced lanthanide fluoroimmunoassay.
DNA was electrophoresed on a 0.7% agarose gel. Comparison was made with negative samples were assigned a value half way between zero and the limit of detection and averaged with the positive values for statistical purposes. c Mean of two animals. a supercoiled molecular marker to determine the purity and integrity of the sample.
d ND, all three samples not detectable at a detection limit of 2 fmol/µg DNA. e NS, no sample.
CisplatinϪDNA adduct measurement by dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA)
CisplatinϪDNA adducts were determined by DELFIA, an adaptation of the mitochondrial DNA adduct levels in brain and liver were enzyme-linked immunosorbent assay (7,11,12) that has been previously described (8). Briefly, microtiter plates were coated with 0.36 ng higher than the corresponding genomic DNA adduct levels.
cisplatinϪDNA modified to 3% with the modification level determined by Comparative data for brain are shown in Figure 1A , where atomic absorbance spectrometry. Plates were blocked with fetal calf serum.
the values for genomic DNA were~7-to 50-fold lower than Rabbit antiserum elicited against cisplatinϪDNA (4.3% modified) was used the values observed for mitochondrial DNA. In fetal liver, as primary antibody (13, 14) at a dilution of 1:120 000 in 2% fetal calf serum. Antibody was incubated with 35 µg sample or standard cisplatin-modified genomic DNA values were~2-to 16-fold lower than those DNA and samples were assayed three times using triplicate experimental and Research Fluorometer (Wallac) at 614 nm. The DELFIA standard curve comprised calf thymus DNA modified with cisplatin to 0.5 pmol Pt/µg DNA, Discussion determined by atomic absorbance spectrometry. The 50% inhibition for 40 standard curves was 0.59Ϯ0.04 pmol Pt/µg DNA. The detection limit was 2
The data presented here demonstrate increased levels of fmol Pt/µg DNA.
cisplatin mitochondrial DNA adducts, as compared with genomic DNA adducts, in livers and brains of maternal and fetal Results rats given one exposure to cisplatin at a tumorigenic level (5 mg/kg body wt) and a toxic level (15 mg/kg body wt) of drug. This study compares cisplatinϪDNA adduct formation in genomic and mitochondrial compartments from pregnant rats
The genomic DNA adduct data presented here have been previously published (8) along with genomic DNA adduct (n ϭ 3) exposed perinatally to a single dose of 5 or 15 mg cisplatin/kg body wt. The drug was given on day 18 of values from many other maternal and fetal tissues. The purpose of this presentation is to underscore the novel observation that gestation and maternal and fetal tissues were obtained 24 h later. CisplatinϪDNA adduct levels were determined by DELFIA in highly elevated mitochondrial DNA adduct levels occur in rat brain and liver, tissues that are targets for tumorigenesis. It is pooled tissues from the fetal rats of each litter and in the corresponding maternal tissues. Fetal rat tissues were pooled interesting to note that the two tissues accumulating cisplatin mitochondrial DNA adducts, liver and brain, are relatively because each fetus provided too little tissue for individual assay. However, with each tissue combined from an average more quiescent at the late stage of gestation, as compared with kidney and placenta. One could postulate that replication of of seven fetuses per litter, there was sufficient DNA to assay each tissue two or three times and consider each litter as a mitochondria accomplishes adduct dilution. Any functional impairment that may have been produced in the mitochondria separate data point.
Values for the maternal tissues, presented in Table I , demonby these high adduct quantities is currently unknown. Future studies will focus on the functional effects of cisplatin exposure strate that the kidney did not have high mitochondrial cisplatinϪDNA adduct levels, liver had essentially similar in this organelle. Mitochondria contain double-stranded circular DNA of adduct levels in both compartments and the brain had much higher levels in mitochondrial DNA as compared with genomic~16 000 bp that has no histones (15) . The lack of histones results in accessibility of mitochondrial DNA to damage from DNA, at both doses assayed.
Values for the fetal tissues, shown in Table II , demonstrate outside influences and is generally considered to contribute substantially to the enhanced binding of carcinogenic chemicals that placenta and kidneys did not give measurable adduct levels in mitochondrial DNA, although low levels of adducts to mitochondrial DNA as compared with genomic DNA. In addition to studies with cisplatin (16, 17) , benzo[a]pyrene were measurable in genomic DNA. In contrast, cisplatin bound to DNA are due both to higher initial cisplatin binding and to inefficient DNA adduct removal.
The transplacental tumorigenicity observed in livers and brains of rats (1) and mice (25) is supported by observations of direct genomic DNA adduction (8). In addition, transplacental cisplatin exposure is associated with ras activation in mouse skin at GpG sites in codons 12 and 13 (26) , suggesting that fetuses may be susceptible to initiation by this drug. The functional consequences of the high levels of mitochondrial cisplatin adduction observed in brain and liver in these experiments and any possible associations with tumorigenesis have not been assessed. Compared with muscle and some other organs, these are not tissues that have high energy requirements. However, there is ample evidence in the literature that exposure to cisplatin can reduce mitochondrial respiratory function and adenosine triphosphate production as well as membraneassociated calcium in rat kidney (27) (28) (29) (30) and in kidneys of cancer patients (31) . In addition, cultured cells made resistant by continued exposure to cisplatin respond by increasing mitochondrial size and function (32,33). Moorehead et al. (34) measured cisplatinϪDNA adduct levels in sensitive and resistant variants of a fibrosarcoma cell line and showed that the resistant cells had half as many DNA adducts and decreased mitochondrial membrane potentials as compared with the parental cells. Both of these responses improve the survival capabilities of the resistant cells (34) . Taken together, all of these studies suggest that high levels of cisplatin adduction in mitochondrial DNA may be responsible for impairment of mitochondrial function. Investigation of mitochondrial integrity in transplacentally exposed rats will be a focus for future investigations. with nude mice carrying a human gingival melanoma (16) suggested that accumulating mitochondrial levels of cisplatin
